Pipeline
UPyTher leverages its proprietary hydrogel-drug formulation platform
to create a pipeline of specialty-products for peritoneal oncology
UPyTher's hydrogel platform has been tested in three different species (i.e. mice, rats and minipigs)
Feasibility of intraperitoneal administration has been demonstrated in a clinical setting in human cadavers
GLP/GMP-compliant development of the hydrogel platform is underway in order to support clinical development of UPT-211 and UPT-122
​
PERITONEAL ONCOLOGY
Discovery
Nonclinical
Clinical
Status
UPT-211
PoC & PK in two species.
Nonclinical toxicity studies are underway to facilitate a FiH trial in 2026.
peritoneal carcinomatosis from
Colorectal Cancer
UPT-122
peritoneal carcinomatosis from
Ovarian Cancer
PoC has been established in rodent models
non-GxP
GxP
PERITONEAL IMMUNO-ONCOLOGY
Discovery
Nonclinical
Clinical
Status
NON-DISCLOSED
peritoneal carcinomatosis from
Colorectal Cancer
UPyTher is evaluating immunomodulatory drugs for intraperitoneal immunotherapy